COVID-19 and Anticoagulants

19 December 2022

Recent evidence shows potentially significant drug interactions may occur between COVID-19 treatments, including Paxlovid, Lagevrio and Veklury and anticoagulants. Broadly speaking:

Lagevrio – there are no reported significant drug interactions with anticoagulants, particularly with Direct Oral Anticoagulants (DOACs) at this time.

Paxlovid – there are important interactions with anticoagulants, particularly with DOACs and also with warfarin.

Veklury – may increase or decrease the anticoagulant effect of warfarin.  Such interactions can impact on laboratory monitoring of anticoagulant use and the safe use of anticoagulants. 

It is advised that drug interactions are checked if patients are commenced on the above-listed COVID-19 treatments. Refer to the product information sheets; additionally, the following links provide information on potentially significant drug interactions: 

It is recommended that you consult with a pharmacist as well as the appropriate clinical services if potentially significant drug interactions are identified.

General News


Newborn Screening program expanded

Newborn Screening program expanded This month, SA Patholog...


Hiss the season

Snakes love to make themselves at home during the warmer wea...


Screening for Down syndrome in pregnancy

SA Pathology’s Biochemical Genetics laboratory receives 20,0...


EDI Client connection issues

To solve the EDI Client connection issues please follow the ...


International Pathology Day

International Pathology Day is 8 November, in recognition of...